MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients
World first - approved for take home in cancer patients experiencing emotional distressMB22001 is a proprietary titratable form of LSD (Lysergic Acid Diethylamide) for convenient take-home MicrodosingOne of two Phase 2 trials currently …
- World first - approved for take home in cancer patients experiencing emotional distress
- MB22001 is a proprietary titratable form of LSD (Lysergic Acid Diethylamide) for convenient take-home Microdosing
- One of two Phase 2 trials currently underway:
- Phase 2A LSD-Microdosing (MB22001) in patients with Major Depressive Disorder, and;
- Phase 2B LSD-Microdosing (MB22001) in patients with late stage Cancer
VANCOUVER, BC / ACCESSWIRE / October 31, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to announce first doses have been administered in MindBio's Phase 2B randomised, double blind and placebo controlled clinical trial in patients with advanced stage cancer who are experiencing emotional distress.
In a world first, this is a Phase 2B government approved take-home trial of a psychedelic medicine (MB22001), a proprietary titratable form of LSD, designed for safe dosing in the community.
In this video, MindBio Chief Executive Officer and Co-founder Justin Hanka discusses the trial and the importance of this scientific work for treating depression and existential distress in advanced stage cancer patients.
Chief Executive Officer of MindBio Justin Hanka said, "Patients with advanced stage cancer experience emotional and existential distress and are commonly treated with anti-depressants and anti-anxiolytic medications that are often not effective and or have undesirable side effects. We hope this treatment provides effective relief of symptoms of depression and anxiety in this vulnerable patient cohort".
MindBio now has two Phase 2 clinical trials underway:
- Phase 2A LSD-Microdosing (MB22001) in patients with Major Depressive Disorder, and;
- Phase 2B LSD-Microdosing (MB22001) in patients with late stage Cancer
MindBio Therapeutics and Chief Executive Officer and Co-founder Justin Hanka have been nominated in a number of profile industry awards. We invite our shareholders to vote here in the link:
VOTE HERE. One Vote per person per day.
Lesen Sie auch
https://awards.wonderlandconference.com/vote/
Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates
Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=tr ...
Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/